Physician profile
Michael Yao
NPI 1427057637
$3,443.37
in general payments reported to CMS, 2019-2025
35 companies · $891 in 2025
The $891 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $555 · 2020: $97.43 · 2021: $29.88 · 2022: $151 · 2023: $643 · 2024: $1,075 · 2025: $891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,609.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $560.70 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $436.04 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $373.08 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $348.09 | 2019-2025 | |
| Glaxosmithkline, LLC. | $342.01 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbott Laboratories | $220.52 | 2021-2025 | Freestyle Libre 3, Eterna |
| Exact Sciences Corporation | $196.30 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $133.70 | 2022-2025 | Spravato |
| Dexcom, INC. | $82.47 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.44 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $57.96 | 2019 | |
| Dynavax Technologies Corporation | $57.88 | 2023-2025 | Heplisav-B |
| Amgen INC. | $53.27 | 2023-2025 | Krystexxa, Repatha, Prolia |
| Genentech USA, INC. | $48.70 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $41.40 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $39.76 | 2023-2024 | Ubrelvy |
| Merck Sharp & Dohme LLC | $37.57 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.79 | 2023-2025 | |
| Inari Medical, INC. | $27.01 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Madrigal Pharmaceuticals | $23.41 | 2025 | Rezdiffra |
| Philips North America LLC | $22.65 | 2024 | (Ck7) Extended Holter |
| Seqirus USA INC | $22.06 | 2024 | Flucelvax, Fluad |
| Alexion Pharmaceuticals, INC. | $20.02 | 2019 | |
| Renalytix Ai, INC. | $19.99 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Inspire Medical Systems, INC. | $19.69 | 2025 | Inspire |
| Esperion Therapeutics, INC. | $19.33 | 2020 | |
| Edwards Lifesciences Corporation | $17.98 | 2024 | Sapien 3 Ultra Resilia |
| Axsome Therapeutics, INC. | $17.60 | 2025 | Auvelity |
| Astellas Pharma US INC | $15.93 | 2025 | Veozah |
| Acerus Pharmaceuticals Corporation | $14.79 | 2022 | |
| Kyowa Kirin, INC. | $14.75 | 2025 | |
| Idorsia Pharmaceuticals US INC | $14.46 | 2024 | Quviviq |
| Medtronic, INC. | $13.30 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.00 | 2019 | |
| Itamar Medical INC | $9.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Yao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.